Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Inclusion Criteria: * Germline BRCA 1/2 Mutation Positive * Women and men at least 18 years of age or older. * Histologically confirmed invasive adenocarcinoma of the breast * HER2 negative breast cancer as defined by ASCO-CAP criteria * Tumor greater than or equal toT1, N0-3 * No evidence of distant metastasis * Adequate bone marrow, hepatic, and renal function * ECOG performance status 0 or 1 Exclusion Criteria: * Any other previous antitumor therapies for the current cancer event. Treatment for ductal carcinoma in situ (DCIS) is allowed; ie, surgery, hormonal therapy and radiation. * Evidence of distant metastasis apparent prior to randomization * Patients with inflammatory breast carcinoma * Malignancy within the last 3 years, except: Stage 1 melanoma which does not require any further treatment after adequate surgical excision; adequately treated non melanoma skin cancer; Curatively treated in situ cancer of the cervix; Stage 1, Grade 1 endometrial carcinoma; or Adequately treated contralateral breast carcinoma which has been disease free for a year; Other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for 5 years. * Previous or concomitant systemic anti cancer therapies used for the treatment of cancer in the last 3 years. * Prior treatment with a PARP inhibitor in any disease setting * Concomitant use of Strong P gp inhibitors or inducers or BCRP inhibitors * Patients who are unwilling or unable to u…